Michael Xin Hui, MBA, is a successful entrepreneur and investor and is Managing Director of Pandect Bioventures. He also serves as Chairman of Quantum Bio (including Shanghai ChemPartner) and ShangPharma. Previously he was Vice President of Investment Banking, Greater China, Softbank Investment E2-Capital, a subsidiary of the leading Japanese investment and venture firm, where he was responsible for managing the Shanghai office operation as well as executing IPO, M&A, and private placement deals in China. He also served as Investment Manager of Phytomedica. In addition, he provided financial advisory services to other companies in China, which included identifying potential joint venture or collaboration partners, developing restructuring and financing strategies, and preparing strategic investment proposals.
Mr. Hui founded and built a China-based global pharmaceutical R&D CRO, ChemPartner, from 5 employees in 2002 to approximately 2000 employees today. In the process he took the CRO business public on the NYSE, and more recently took the privatized company public again on the Shenzhen exchange through M&A with Quantum. He has also founded and invested in multiple other biotech companies in China, Taiwan, and the U.S., several of which have advanced their programs into human clinical trials.
Mr. Hui received his bachelor’s and master’s degrees in chemistry from Oregon State University and Tulane University, respectively. After graduate school, he worked as a research scientist and project manager at American Home Products (which became Wyeth and then Pfizer) and went on to complete his MBA at the Stern School of Business at New York University.